How To Better Support Individuals With Bipolar 1 Disorder

Jun 27, 2022 2:00 PM ET

We’re committed to listening to mental health providers and learning how we can better help them support individuals with bipolar 1 disorder.

Our survey of psychiatrists conducted with The Harris Poll & Depression and Bipolar Support Alliance – National Headquarters uncovered varying answers for why individuals may stop taking their medication.

About Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at